US · MESO
Mesoblast Limited
- Sector
- Healthcare · Biotechnology
- Headquarters
- Melbourne, VIC 3000
- Website
- mesoblast.com
Price · as of 2025-06-30
$15.74
Market cap 2.04B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $48.04 | +205.21% |
| Intrinsic Value(DCF) | $6.76 | -57.05% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $80.96 | $337,786.82 | $4.92 | $15.98 | $3,543,761.90 |
| 2012 | $67.40 | $74.71 | $6.26 | $0.13 | $75.81 |
| 2013 | $51.20 | $44.71 | $6.22 | $3.61 | $17.88 |
| 2014 | $49.80 | $37.80 | $5.82 | $0.49 | $1.87 |
| 2015 | $24.52 | $26.85 | $5.56 | $0.00 | $0.21 |
| 2016 | $9.22 | $36.40 | $3.72 | $6.94 | $0.00 |
| 2017 | $11.76 | $32.26 | $5.71 | $0.00 | $117.39 |
| 2018 | $11.96 | $86.83 | $5.56 | $5.05 | $0.00 |
| 2019 | $10.08 | $24.11 | $4.96 | $0.00 | $0.00 |
| 2020 | $33.44 | $43.80 | $5.11 | $0.48 | $0.00 |
| 2021 | $12.46 | $27.03 | $5.65 | $0.00 | $106.69 |
| 2022 | $6.08 | $26.93 | $3.44 | $0.00 | $0.00 |
| 2023 | $3.04 | $25.30 | $3.39 | $0.00 | $16.92 |
| 2024 | $6.10 | $26.82 | $2.61 | $0.00 | $11.00 |
| 2025 | $14.39 | $48.04 | $2.25 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates Mesoblast Limited's (MESO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $48.04
- Current price
- $15.74
- AI upside
- +205.21%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$6.76
-57.05% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| MESO | Mesoblast Limited | $15.74 | 2.04B | +205% | -57% | — | — | -17.02 | 2.91 | 101.06 | -23.15 | — | 67.85 | 70.17% | -363.08% | -593.92% | -18.95% | -11.34% | -14.05% | 0.21 | -2.72 | 1.99 | 1.72 | 0.45 | -562.00% | 19139.00% | 388.00% | -2.92% | -0.49 | -9.21% | 0.00% | 0.00% | 5.14% | -27.31 | -33.64 | 99.14 | 3.68 |
| COGT | Cogent Biosciences, Inc. | $38.85 | 6.31B | — | — | — | — | -7.99 | 4.13 | — | -6.03 | -218.46 | 4.13 | 0.00% | — | — | -73.70% | 2714.02% | -51.99% | 0.40 | -108.87 | 14.23 | 14.08 | 0.18 | 366.00% | — | 2766.00% | -10.12% | -4.13 | 2165.58% | 0.00% | 0.00% | 0.00% | -5.94 | -7.45 | — | 3.37 |
| EWTX | Edgewise Therapeutics, In… | $30.44 | 3.22B | — | — | — | — | -18.22 | 5.85 | — | -13.38 | -146.76 | 5.85 | 0.00% | — | — | -34.19% | 3798.11% | -32.29% | 0.01 | — | 19.85 | 19.37 | 0.30 | 1241.00% | — | 3057.00% | -4.71% | -5.25 | 2858.86% | 0.00% | 0.00% | 0.66% | -13.22 | -17.57 | — | 59.04 |
| GLPG | Galapagos N.V. | $33.66 | 2.22B | +251% | +430,280% | +154% | +4,930% | 6.01 | 0.60 | 1.73 | -1.90 | 1.80 | 0.60 | 93.49% | 40.56% | 28.85% | 10.47% | 2205.83% | 8.51% | 0.00 | 164.04 | 20.15 | 19.95 | -0.14 | 33304.00% | 30348.00% | -4967.00% | -10.50% | -1.24 | -989.65% | 0.00% | 0.00% | 1.20% | -2.34 | 5.22 | -0.95 | 8.66 |
| GPCR | Structure Therapeutics In… | $62.98 | 3.63B | — | — | — | — | -26.37 | 2.46 | — | -16.39 | -1028.46 | 2.46 | 0.00% | — | — | -11.86% | -570.89% | -11.35% | 0.00 | — | 24.81 | 22.85 | 5.69 | 256.00% | — | 9149.00% | -6.06% | -3.51 | -730.15% | 0.00% | 0.00% | 16.85% | -12.94 | -10.11 | — | 33.44 |
| IBRX | ImmunityBio, Inc. | $9.78 | 9.63B | +901% | -57% | — | — | — | -19.22 | 84.77 | -45.80 | — | -18.70 | 99.34% | -226.00% | -310.18% | 0.00% | -52123.97% | 0.00% | -1.76 | -2.28 | 5.10 | 4.62 | -3.53 | -3871.00% | 66831.00% | -2341.00% | -3.18% | -4.94 | -62105.09% | 0.00% | — | 0.00% | -39.99 | -33.58 | 90.38 | -5.49 |
| LQDA | Liquidia Corporation | $31.02 | 2.7B | -15% | +1,142% | — | -41% | -8.95 | 15.09 | 83.34 | -9.61 | -24.05 | 16.61 | 58.00% | -866.63% | -931.65% | -209.35% | -667.62% | -74.80% | 1.58 | -9.71 | 4.43 | 4.29 | 0.47 | 3719.00% | -1997.00% | 12955.00% | -8.43% | -2.24 | -541.45% | 0.00% | 0.00% | 1.71% | -9.17 | -11.31 | 79.48 | 0.24 |
| NUVB | Nuvation Bio Inc. | $5.91 | 2.02B | — | — | — | — | -0.96 | 1.17 | 68.96 | -0.09 | -0.19 | 1.18 | 10.10% | -7527.33% | -7213.76% | -106.27% | 3695.49% | -97.74% | 0.02 | -1737.91 | 9.04 | 8.91 | 0.05 | 50286.00% | — | 9183.00% | -24.05% | -2.24 | 814.24% | 0.00% | 0.00% | 0.00% | -0.08 | -0.38 | 6.24 | -0.68 |
| OCUL | Ocular Therapeutix, Inc. | $8.94 | 1.95B | +214% | -39% | — | +53% | -7.73 | 3.14 | 39.67 | -5.60 | -47.16 | 3.14 | 87.31% | -521.04% | -513.17% | -54.85% | 13699.49% | -42.01% | 0.12 | -22.82 | 15.39 | 15.11 | 2.63 | 1639.00% | -1867.00% | 5952.00% | -10.55% | -4.03 | 11004.21% | 0.00% | 0.00% | 16.58% | -5.18 | -6.45 | 26.99 | 6.07 |
| QURE | uniQure N.V. | $15.63 | 962.87M | +52% | -69% | — | — | -2.48 | -88.12 | 21.94 | -1.83 | — | -5.94 | 32.42% | -679.58% | -883.35% | -238.46% | 63.55% | -34.51% | -9.78 | -2.89 | 9.74 | 9.32 | 0.58 | -2396.00% | 7117.00% | 2157.00% | -31.28% | -4.56 | 64.17% | 0.00% | 0.00% | 0.00% | -1.59 | -1.58 | 10.82 | -2.50 |
| VRDN | Viridian Therapeutics, In… | $29.38 | 2.39B | +11,973% | +7,221% | — | — | -7.49 | 3.55 | 36.21 | -5.16 | — | 3.55 | 98.36% | -512.91% | -483.57% | -49.16% | 573.89% | -41.73% | 0.07 | -73.44 | 12.65 | 12.37 | 0.48 | -1658.00% | 2335993.00% | 1892.00% | -10.79% | -3.91 | 437.27% | 0.00% | 0.00% | 3.24% | -4.79 | -6.29 | 24.58 | 6.44 |
About Mesoblast Limited
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
- CEO
- Silviu Itescu
- Employees
- 73
- Beta
- 2.17
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($6.76 ÷ $15.74) − 1 = -57.05% (DCF, example).